Experimental oral therapy for high-risk CLL shows promise

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen

ASH 2015: New targeted therapies for haematological malignancies

Using epigenetics to manipulate cancer cells

Overcoming the barriers of the P53 dysfunction to cure blood cancers

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

First targeted therapy for multiple myeloma effective against hard-to-treat disease

First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival

Exciting evidence for first all-oral treatment for relapsed and treatment-resistant multiple myeloma